ICON Public Limited Company (ICLR) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $211.50 (-1.94%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 23, 2026 | David Windley | Jefferies | $135.00 | -36.2% |
| Feb 17, 2026 | Jamie Clark | Redburn Partners | $100.00 | -52.7% |
| Feb 12, 2026 | Sean Dodge | BMO Capital | $100.00 | -52.7% |
| Feb 12, 2026 | Michael Cherny | Leerink Partners | $105.00 | -50.4% |
| Dec 15, 2025 | Luke Sergott | Barclays | $200.00 | -5.4% |
| Oct 2, 2025 | Luke Sergott | Barclays | $190.00 | -10.2% |
| Sep 9, 2025 | David Windley | Jefferies | $175.00 | -17.3% |
| Oct 28, 2024 | Jailendra Singh | Truist Financial | $295.00 | +39.5% |
| Oct 24, 2024 | Michael Cherny | Leerink Partners | $376.00 | +77.8% |
| Oct 14, 2024 | Jailendra Singh | Truist Financial | $363.00 | +71.6% |
| Sep 20, 2024 | Eric Coldwell | Robert W. Baird | $340.00 | +60.8% |
| Sep 18, 2024 | Michael Cherny | Leerink Partners | $379.00 | +79.2% |
| Jul 8, 2024 | Eric Coldwell | Robert W. Baird | $376.00 | +77.8% |
| Jun 6, 2024 | Matthew Sykes | Goldman Sachs | $370.00 | +74.9% |
| May 31, 2024 | Eric Coldwell | Robert W. Baird | $367.00 | +73.5% |
| May 31, 2024 | David Windley | Jefferies | $390.00 | +84.4% |
| May 30, 2024 | Elizabeth Anderson | Evercore ISI | $360.00 | +70.2% |
| Oct 6, 2022 | Luke Sergott | Barclays | $215.00 | +1.7% |
| Aug 4, 2021 | Katie Tryhane | Credit Suisse | $250.00 | +18.2% |
| Jul 23, 2021 | Dan Leonard | Wells Fargo | $280.00 | +32.4% |
Top Analysts Covering ICLR
ICLR vs Sector & Market
| Metric | ICLR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.61 | 2.25 | 2.41 |
| Analyst Count | 31 | 8 | 19 |
| Target Upside | +2.9% | +153002.0% | +21.5% |
| P/E Ratio | 34.33 | 3.44 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.71B | $7.92B | $8.06B | 11 |
| 2027-12-31 | $7.99B | $8.24B | $8.46B | 9 |
| 2028-03-30 | $2.01B | $2.04B | $2.06B | 1 |
| 2028-06-30 | $2.03B | $2.06B | $2.08B | 1 |
| 2028-09-30 | $2.07B | $2.10B | $2.12B | 1 |
| 2028-12-30 | $2.09B | $2.12B | $2.14B | 1 |
| 2028-12-31 | $8.65B | $8.67B | $8.69B | 9 |
| 2029-03-30 | $2.21B | $2.24B | $2.26B | 1 |
| 2029-06-30 | $2.23B | $2.27B | $2.29B | 1 |
| 2029-09-30 | $2.29B | $2.32B | $2.35B | 1 |
| 2029-12-30 | $2.32B | $2.35B | $2.38B | 1 |
| 2029-12-31 | $8.64B | $8.94B | $9.14B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $10.38 | $12.30 | $13.06 | 10 |
| 2027-12-31 | $11.57 | $13.37 | $14.97 | 6 |
| 2028-03-30 | $3.20 | $3.27 | $3.31 | 2 |
| 2028-06-30 | $3.22 | $3.28 | $3.32 | 2 |
| 2028-09-30 | $3.28 | $3.34 | $3.38 | 2 |
| 2028-12-30 | $3.51 | $3.58 | $3.63 | 2 |
| 2028-12-31 | $10.47 | $14.86 | $18.49 | 6 |
| 2029-03-30 | $4.71 | $4.80 | $4.86 | 1 |
| 2029-06-30 | $4.85 | $4.95 | $5.01 | 1 |
| 2029-09-30 | $5.10 | $5.20 | $5.27 | 1 |
| 2029-12-30 | $5.26 | $5.36 | $5.43 | 1 |
| 2029-12-31 | $15.01 | $15.69 | $16.15 | 4 |
Frequently Asked Questions
What is the analyst consensus for ICLR?
The consensus among 31 analysts covering ICON Public Limited Company (ICLR) is Hold with an average price target of $170.64.
What is the highest price target for ICLR?
The highest price target for ICLR is $390.00, set by David Windley at Jefferies on 2024-05-31.
What is the lowest price target for ICLR?
The lowest price target for ICLR is $100.00, set by Sean Dodge at BMO Capital on 2026-02-12.
How many analysts cover ICLR?
31 analysts have issued ratings for ICON Public Limited Company in the past 12 months.
Is ICLR a buy or sell right now?
Based on 31 analyst ratings, ICLR has a consensus rating of Hold (2.61/5) with a +2.9% upside to the consensus target of $170.64.
What are the earnings estimates for ICLR?
Analysts estimate ICLR will report EPS of $12.30 for the period ending 2026-12-31, with revenue estimated at $7.92B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.